Pharma major Lupin has received approval for its Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc's Lipitorfl Tablets, 10 mg, 20 mg, 40 mg and 80 mg.
Lupin's Atorvastatin Calcium Tablets USP 10 mg, 20 mg, 40 mg, and 80 mg, is the generic version of Pfizer Inc's Lipitor® Tablets, 10 mg, 20 mg, 40 mg and 80 mg. It is indicated to lower cholesterol in blood for adults and children over 10 years of age. Atorvastatin is also prescribed to lower the risk for heart attack, stroke in patients with cardiovascular diseases, diabetes and other risk factors such as eye problems, kidney diseases or high blood pressure.
Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg had annual sales of approximately USD 696 million in the US (JQVIA MAT December 2018).
Shares of LUPIN LTD. was last trading in BSE at Rs.791.1 as compared to the previous close of Rs. 788.65. The total number of shares traded during the day was 98048 in over 2835 trades.
The stock hit an intraday high of Rs. 803.1 and intraday low of 786.5. The net turnover during the day was Rs. 78078000.